Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – Analysts at William Blair upped their FY2017 EPS estimates for Aclaris Therapeutics in a research note issued on Wednesday. William Blair analyst T. Lugo now expects that the biotechnology company will post earnings of ($2.65) per share for the year, up from their previous estimate of ($3.16). William Blair also issued estimates for Aclaris Therapeutics’ Q4 2017 earnings at ($0.88) EPS, FY2018 earnings at ($4.71) EPS, FY2019 earnings at ($2.07) EPS and FY2020 earnings at $0.30 EPS.

Several other research firms also recently commented on ACRS. BidaskClub raised shares of Aclaris Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, July 24th. Cantor Fitzgerald set a $50.00 price target on shares of Aclaris Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, August 9th. Zacks Investment Research downgraded shares of Aclaris Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $36.00 price target on shares of Aclaris Therapeutics in a research note on Monday, July 31st. Finally, JMP Securities reaffirmed an “outperform” rating and issued a $39.00 price target on shares of Aclaris Therapeutics in a research note on Friday, September 8th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company. Aclaris Therapeutics has a consensus rating of “Buy” and a consensus target price of $39.20.

ILLEGAL ACTIVITY NOTICE: “William Blair Brokers Raise Earnings Estimates for Aclaris Therapeutics, Inc. (ACRS)” was first published by Watch List News and is the property of of Watch List News. If you are viewing this article on another site, it was illegally stolen and reposted in violation of US & international copyright laws. The legal version of this article can be viewed at https://www.watchlistnews.com/william-blair-brokers-raise-earnings-estimates-for-aclaris-therapeutics-inc-acrs/1697201.html.

Aclaris Therapeutics (ACRS) opened at $23.23 on Friday. Aclaris Therapeutics has a 12 month low of $20.20 and a 12 month high of $33.25.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.63) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.86) by $0.23. The firm had revenue of $0.68 million during the quarter, compared to analysts’ expectations of $2.00 million.

In other news, Director Andrew N. Schiff purchased 108,601 shares of the stock in a transaction dated Wednesday, August 16th. The shares were acquired at an average cost of $23.02 per share, for a total transaction of $2,499,995.02. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 16.30% of the stock is currently owned by company insiders.

Several large investors have recently added to or reduced their stakes in ACRS. Wells Fargo & Company MN boosted its holdings in shares of Aclaris Therapeutics by 91.3% in the 1st quarter. Wells Fargo & Company MN now owns 12,359 shares of the biotechnology company’s stock valued at $369,000 after buying an additional 5,900 shares in the last quarter. Parametric Portfolio Associates LLC raised its position in shares of Aclaris Therapeutics by 67.0% in the 1st quarter. Parametric Portfolio Associates LLC now owns 55,397 shares of the biotechnology company’s stock valued at $1,652,000 after purchasing an additional 22,223 shares during the last quarter. American International Group Inc. raised its position in shares of Aclaris Therapeutics by 31.3% in the 1st quarter. American International Group Inc. now owns 6,804 shares of the biotechnology company’s stock valued at $203,000 after purchasing an additional 1,623 shares during the last quarter. Alliancebernstein L.P. raised its position in shares of Aclaris Therapeutics by 24.0% in the 1st quarter. Alliancebernstein L.P. now owns 9,300 shares of the biotechnology company’s stock valued at $277,000 after purchasing an additional 1,800 shares during the last quarter. Finally, PNC Financial Services Group Inc. raised its position in shares of Aclaris Therapeutics by 57.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 7,320 shares of the biotechnology company’s stock valued at $218,000 after purchasing an additional 2,680 shares during the last quarter. Institutional investors and hedge funds own 95.85% of the company’s stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Earnings History and Estimates for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.